Crystalys Therapeutics

$130.0M Series B

Announced: Jul 23, 2026
Sector: Biotechnology
Investors: 8

Summary

Crystalys Therapeutics completed a $130 million Series B financing round led by Frazier Life Sciences. The company said it will use the capital to advance dotinurad into global Phase 3 trials and prepare for commercialization. Crystalys Therapeutics is a biopharmaceutical company developing gout treatments.

Investors

Frazier Life Sciences, Novo Holdings, SR One, Catalys Pacific, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management